menu search

GNLX / Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer
Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary candidate, Olvi-Vec, a cancer treatment that targets and destroys cancer cells. The company recently raised $18 million through the private placement of 900,000 shares, and its cash runway is projected to extend into Q1 2026, allowing it to pursue its objectives and strategies. Genelux's Olvi-Vec has shown promising results in clinical trials, demonstrating its capacity to penetrate and multiply within distant tumor sites. Read More
Posted: Jul 11 2023, 04:12
Author Name: Seeking Alpha
Views: 080933

GNLX News  

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

By Seeking Alpha
July 11, 2023

Genelux: A Game Changer In Platinum-Resistant Ovarian Cancer

Genelux, an immuno-oncology frontrunner, has secured over $65 million in financing and is conducting successful clinical trials for its primary candid more_horizontal

Why Shares of Genelux Corporation Jumped This Week

By The Motley Fool
June 1, 2023

Why Shares of Genelux Corporation Jumped This Week

Genelux focuses on hard-to-treat cancers. Its lead therapy is Olvi-Vec, which did well in a phase 2 trial to treat ovarian cancer. more_horizontal

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

By Seeking Alpha
March 26, 2023

Genelux: Recent IPO With Phase 3 Stage Oncolytic Virus Cancer Therapy

GNLX IPO-ed recently, but the company has been around for two decades. The company develops an oncolytic virus targeting cancer. more_horizontal

Genelux IPO prices at bottom of range

By Market Watch
January 26, 2023

Genelux IPO prices at bottom of range

Genelux Corp. priced its initial public offering at $6 a share, the low end of its $6 to $7 a share range, for its stock market debut Thursday on the more_horizontal


Search within

Pages Search Results: